DMPK CONSULTING SUPPORT SERVICES
DMPK CONSULTING SUPPORT SERVICES
批准号:
10495521
负责人:
PAUL PEARSON
金额:
$1.32万
依托单位:
--
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-23 至
关键词:
AddressChemistryClinical ResearchConsultConsultationsContractorDataData AnalysesDevelopmentDrug KineticsExperimental DesignsFormulationIndividualLeadProtocols documentationResearch DesignRoleServicesStrategic PlanningUnited States National Institutes of Healthassay developmentdesigndrug developmentdrug discoverydrug metabolismlead optimizationprograms
中文摘要
药物代谢和药代动力学(DMPK)顾问可能需要
评估PK研究方案和数据,协助研究设计,并向NIH工作人员提供以下建议
建立与DMPK相关的里程碑。具体的咨询职责
将取决于个人顾问的专业知识和个人需求
项目。可能需要与DMPK相关的临时咨询服务或
LDTS。
药物代谢和药代动力学顾问的作用可能包括但不包括
仅限于以下职责和任务:
·与其他顾问、承包商和NIH工作人员合作,提供建议,
战略性规划和管理药代动力学(PK)计划,以促进化验
开发,探索化学,铅优化,配方活动,
IND使能和临床研究。
·担任PK专家,以确定潜在的药物发现和
发展挑战,如潜在客户识别和潜在客户发展以及
提出应对这些挑战的策略。
·合作设计调查性PK研究、PK/PD策略、实验
发现和翻译项目的设计、数据分析和解释
支持美国国立卫生研究院药物发现和开发项目。
英文摘要
Drug Metabolism and Pharmacokinetics (DMPK) consultants may be required to
evaluate PK study protocols and data, assist with study design, and advise NIH staff on
the establishment of milestones related to DMPK. Specific consulting responsibilities
will depend on the expertise of the individual consultant and the needs of individual
projects. DMPK-related consultation services may be required on an ad hoc basis or on
LDTs.
The role of the Drug Metabolism and Pharmacokinetics consultant may include but is not
limited to the following responsibilities and tasks:
• In partnership with other consultants, contractors, and the NIH staff, advise,
strategically plan, and manage pharmacokinetic (PK) programs to facilitate assay
development, exploratory chemistry, lead optimization, formulation activities,
IND enabling, and clinical studies.
• Serve as the PK expert in order to identify potential drug discovery and
development challenges such as lead identification and lead development and
suggest strategies to address these challenges.
• Collaborate on design of investigative PK studies, PK/PD strategy, experimental
design, data analysis and interpretation for discovery and translational projects in
support of NIH drug discovery and development projects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SUBJECT MATTER EXPERT CONSULTANT FOR DRUG METABOLISM PHARMACOKINETICS [DMPK].
-
批准号:10721124
-
项目类别:
-
资助金额:$1.32万
-
财政年份:2022
-
负责人:PAUL PEARSON
-
依托单位:--
SUBJECT MATTER EXPERT CONSULTANT FOR DRUG METABOLISM PHARMACOKINETICS [DMPK].
-
批准号:10788018
-
项目类别:
-
资助金额:$7.7万
-
财政年份:2022
-
负责人:PAUL PEARSON
-
依托单位:--
SUBJECT MATTER EXPERT CONSULTANT FOR DRUG METABOLISM PHARMACOKINETICS [DMPK].
-
批准号:10721125
-
项目类别:
-
资助金额:$1.32万
-
财政年份:2022
-
负责人:PAUL PEARSON
-
依托单位:--
SUBJECT MATTER EXPERT CONSULTANT FOR DRUG METABOLISM PHARMACOKINETICS [DMPK].
-
批准号:10788017
-
项目类别:
-
资助金额:$2.2万
-
财政年份:2022
-
负责人:PAUL PEARSON
-
依托单位:--
DMPK CONSULTING SUPPORT SERVICES
-
批准号:10619428
-
项目类别:
-
资助金额:$4.84万
-
财政年份:2021
-
负责人:PAUL PEARSON
-
依托单位:--
NIH DRUG DEVELOPMENT CONSULTING SERVICES
-
批准号:8356074
-
项目类别:
-
资助金额:$1.8万
-
财政年份:2011
-
负责人:PAUL PEARSON
-
依托单位:
NIH DRUG DEVELOPMENT CONSULTING SERVICES
-
批准号:8429009
-
项目类别:
-
资助金额:$5.8万
-
财政年份:2011
-
负责人:PAUL PEARSON
-
依托单位:
NIH DRUG DEVELOPMENT CONSULTING SERVICES
-
批准号:9035331
-
项目类别:
-
资助金额:$3.6万
-
财政年份:2011
-
负责人:PAUL PEARSON
-
依托单位:--
TAS::75 0849::TAS TOPIC 255 SELECTIVE AND POTENT INHIBITORS OF TUMOR SPECIFIC GL
-
批准号:8351294
-
项目类别:
-
资助金额:$18.31万
-
财政年份:2011
-
负责人:PAUL PEARSON
-
依托单位:
NIH DRUG DEVELOPMENT CONSULTING SERVICES
-
批准号:8844712
-
项目类别:
-
资助金额:$3.6万
-
财政年份:2011
-
负责人:PAUL PEARSON
-
依托单位:--
NIH DRUG DEVELOPMENT CONSULTING SERVICES
-
批准号:8602417
-
项目类别:
-
资助金额:$11.2万
-
财政年份:2011
-
负责人:PAUL PEARSON
-
依托单位:
国内基金
海外基金
SCIENCE CHINA Chemistry
-
批准号:21224001
-
项目类别:专项基金项目
-
资助金额:24.0万元
-
批准年份:2012
-
负责人:朱晓文
-
依托单位:
Science China Chemistry
-
批准号:21024801
-
项目类别:专项基金项目
-
资助金额:24.0万元
-
批准年份:2010
-
负责人:朱晓文
-
依托单位:
运用Linkage Chemistry合成新型聚合物缀合物和刷形共聚物
-
批准号:20974058
-
项目类别:面上项目
-
资助金额:12.0万元
-
批准年份:2009
-
负责人:袁金颖
-
依托单位: